schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Olanzapn (5 to 20 mg/day) or respredone (1 to 6 mg/day). Intervention 2: Placebo.
Treatment - Drugs
Placebo
Olanzapn (5 to 20 mg/day) or respredone (1 to 6 mg/day)
Sponsors
Vice chancellor for research, Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusive criteria: Diagnosed schizophrenia in accordance with DSM-IV, needs to be applied electroconvulsive therapy (ECT) determined by psychiatrist; providing written informed consent. Exclusion Criteria: Patient who does not volunteer himself or herself, Serious neurological or medical damage such as epilepsy, diabetes, cardiac disease or autistic disorder.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Positive and Negative Syndrome Scale for schizophrenia (PANSS). Timepoint: before first ECT session and about 4 weeks after the last session of ECT. Method of measurement: Interview. | — |
Secondary
| Measure | Time frame |
|---|---|
| A modified version of Mini Mental Status Evaluation. Timepoint: before first ECT session, after every session of ECT, and about 4 weeks after the last session of ECT. Method of measurement: interview. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed